118 related articles for article (PubMed ID: 33409616)
21. Immunohistochemical and proteomic profile of melanotic medulloblastoma.
Zanini C; Mandili G; Pulerà F; Morra I; Peretta P; Turrini F; Forni M
Pediatr Blood Cancer; 2009 Jul; 52(7):875-7. PubMed ID: 19061219
[TBL] [Abstract][Full Text] [Related]
22. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
[TBL] [Abstract][Full Text] [Related]
23. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.
Archer TC; Ehrenberger T; Mundt F; Gold MP; Krug K; Mah CK; Mahoney EL; Daniel CJ; LeNail A; Ramamoorthy D; Mertins P; Mani DR; Zhang H; Gillette MA; Clauser K; Noble M; Tang LC; Pierre-François J; Silterra J; Jensen J; Tamayo P; Korshunov A; Pfister SM; Kool M; Northcott PA; Sears RC; Lipton JO; Carr SA; Mesirov JP; Pomeroy SL; Fraenkel E
Cancer Cell; 2018 Sep; 34(3):396-410.e8. PubMed ID: 30205044
[TBL] [Abstract][Full Text] [Related]
24. Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment.
Stensvold E; Krossnes BK; Lundar T; Due-Tønnessen BJ; Frič R; Due-Tønnessen P; Bechensteen AG; Myklebust TÅ; Johannesen TB; Brandal P
Acta Oncol; 2017 May; 56(5):698-705. PubMed ID: 28325133
[TBL] [Abstract][Full Text] [Related]
25. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
26. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
[TBL] [Abstract][Full Text] [Related]
27. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
[TBL] [Abstract][Full Text] [Related]
28. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical investigation of topoIIβ, H3K27me3 and JMJD3 expressions in medulloblastoma.
Chen J; Zhao J; Zhou X; Liu S; Yan Y; Wang Y; Cao C; Han S; Zhou N; Xu Y; Zhao J; Yan Y; Cui H
Pathol Res Pract; 2017 Aug; 213(8):975-981. PubMed ID: 28554742
[TBL] [Abstract][Full Text] [Related]
30. Proteomic studies of pediatric medulloblastoma tumors with 17p deletion.
Anagnostopoulos AK; Papathanassiou C; Karamolegou K; Anastasiadou E; Dimas KS; Kontos H; Koutsopoulos A; Prodromou N; Tzortzatou-Stathopoulou F; Tsangaris GT
J Proteome Res; 2015 Feb; 14(2):1076-88. PubMed ID: 25543836
[TBL] [Abstract][Full Text] [Related]
31. Paracrine regulation of colony-stimulating factor-1 in medulloblastoma: implications for pathogenesis and therapeutic interventions.
Papavasiliou AK; Mehler MF; Mabie PC; Marmur R; Qingbin S; Keating RF; Kessler JA
Neurosurgery; 1997 Oct; 41(4):916-23. PubMed ID: 9316054
[TBL] [Abstract][Full Text] [Related]
32. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
[TBL] [Abstract][Full Text] [Related]
33. Molecular Classification of Medullobastomas by Whole Genome Expression Profiling.
Nosková H; Adamcová S; Knoflíčková LDR; Pavelka Z; Vejmělková K; Zitterbart K; Slabý O; Štěrba J
Klin Onkol; 2019; 32(Supplementum1):171-173. PubMed ID: 31064192
[TBL] [Abstract][Full Text] [Related]
34. Proteome and miRNome profiling of microvesicles derived from medulloblastoma cell lines with stem-like properties reveals biomarkers of poor prognosis.
Kaid C; Assoni A; Marçola M; Semedo-Kuriki P; Bortolin RH; Carvalho VM; Okamoto OK
Brain Res; 2020 Mar; 1730():146646. PubMed ID: 31917138
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
36. Medulloblastoma: Distinctive Histo-Molecular Correlation with Clinical Profile, Radiologic Characteristics, and Surgical Outcome.
Narayan V; Sugur H; Jaiswal J; Arvinda HR; Arivazhagan A; Somanna S; Santosh V
Pediatr Neurosurg; 2019; 54(5):329-340. PubMed ID: 31480064
[TBL] [Abstract][Full Text] [Related]
37. Dysregulated circular RNAs in medulloblastoma regulate proliferation and growth of tumor cells via host genes.
Lv T; Miao YF; Jin K; Han S; Xu TQ; Qiu ZL; Zhang XH
Cancer Med; 2018 Dec; 7(12):6147-6157. PubMed ID: 30402980
[TBL] [Abstract][Full Text] [Related]
38. Classic and desmoplastic medulloblastoma: complete case reports and characterizations of two new cell lines.
Holthouse DJ; Dallas PB; Ford J; Fabian V; Murch AR; Watson M; Wong G; Bertram C; Egli S; Baker DL; Kees UR
Neuropathology; 2009 Aug; 29(4):398-409. PubMed ID: 19077040
[TBL] [Abstract][Full Text] [Related]
39. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
[TBL] [Abstract][Full Text] [Related]
40. Review of the prognostic factors in medulloblastoma of children and adults.
Brandes AA; Paris MK
Crit Rev Oncol Hematol; 2004 May; 50(2):121-8. PubMed ID: 15157661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
